Unapproved GLP-1 Drugs Sold Online: What JAMA Found
A JAMA Medical News investigation published October 9 documents that unapproved versions of the GLP-1 drugs retatrutide and zenagamtide are widely available for purchase online — at prices that often exceed what the approved alternatives would cost.
The article, by lead senior staff writer Rita Rubin, examines the reasons behind the growing black market for these drugs and the potential risks associated with their use. The reporting is noteworthy not because it reveals something new about online peptide availability — that has been documented elsewhere — but because it places the phenomenon in a major general medical journal with a broad readership.
What the investigation found
JAMA surveyed several online vendors selling unapproved formulations of retatrutide and a newer compound called zenagamtide. Both are GLP-1 receptor agonists in development for weight management and metabolic disease. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, is still in clinical trials and has not received FDA approval for any indication. Zenagamtide is even earlier in development.
The prices JAMA documented were not discounts — they carried a premium over what patients might pay for approved GLP-1 therapies through legitimate channels. This reverses the usual assumption that unregulated markets undercut official ones.
What this means for the research-grade landscape
For the community of people who source research-grade peptides, the JAMA report serves as a useful external confirmation of what is already understood: the online supply chain for unapproved compounds operates outside any regulatory framework. A vial labelled “retatrutide” may contain the stated compound, a different GLP-1, or something unrelated entirely.
This is where the distinction between “unapproved” and “untested” becomes critical. The fact that a compound is sold for research purposes does not automatically mean it is without quality controls — but those controls are voluntary, vendor-dependent, and inconsistently disclosed. A certificate of analysis from an independent laboratory is the closest thing the research-grade market has to a quality signal; whether the certificate matches the batch in the vial is a separate question, which is what batch-specific testing is designed to answer.
The role of third-party testing
An unapproved drug sold online is a regulatory problem. A research compound sold with a verifiable third-party COA is a transparency question. The two are related but not identical, and the JAMA piece does not distinguish between them — understandably, since its audience is clinical rather than research-oriented.
What the JAMA investigation reinforces is the importance of verifiable, batch-specific testing documentation. A screenshot of a COA from a different lot number is not evidence of what the vial in hand contains. A COA whose lab URL resolves to a working .edu or .com domain, with a report number that can be cross-referenced, is the beginning of a verifiable chain.
What comes next
As GLP-1 receptor agonists become the most-prescribed drug class in medicine, the market for unapproved versions — whether sold as “research chemicals” or under other labels — will only grow. The JAMA investigation is a signal that mainstream medical attention is turning toward this supply chain. Whether that attention leads to enforcement action, to industry self-regulation through verified testing standards, or simply to more informed buyers remains to be seen.
For now, the actionable takeaway is unchanged from what it was before JAMA looked into it: when the active ingredient is uncertain, the only way to know what is in the vial is to test it, and the only way to trust the test is to verify it with the issuing laboratory.
The Retatrutide reference protocol is maintained on ResearchProtocols for those who want the compound’s background independently of any vendor claim. For current certificate data across testing laboratories and compounds, the CertIQX index provides a searchable record of over 33,000 indexed COAs.